Media Mosiac Gov Solutions Book a Strategy Call
Gov.MediaMosiac β€Ί GovCon News
πŸ› GovCon Intel Opportunities Presolicitations Contract Awards Award Notices Grants Events Regulatory Search πŸ“ Insights
← Back to Regulatory Updates

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec

Notice
Health and Human Services Department, Food and Drug Administration
Notice
July 8, 2026
2026-13810

πŸ“„ Summary

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
🎯 Get GovCon Intel Free β†’